TrialClinical and translational science2020

Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.

Minna Lehtisalo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.